DermTech Management to Participate in Upcoming Investor Conferences
DermTech (NASDAQ: DMTK) announced its participation in upcoming investor conferences. The company will present at the 41st Annual William Blair Growth Stock Conference on June 1, 2021, at 4:20 PM ET, with a live webcast available on its website. DermTech will also attend the 18th Annual Craig-Hallum Institutional Investor Conference on June 2, 2021. DermTech leads in precision dermatology, utilizing a non-invasive skin genomics platform to enhance skin cancer detection and treatment personalization. More details can be found on DermTech’s investor relations site.
- None.
- None.
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that its management will participate at the following investor conferences:
-
41st Annual William Blair Growth Stock Conference
Presenting on Tuesday, June 1, 2021 at 4:20 p.m. Eastern Time
Interested parties may access the live webcast of the presentation and, for 30 days following the William Blair conference, the archived webcast of the presentation through the “Investor Relations” section of DermTech’s website at: www.DermTech.com.
-
18th Annual Craig-Hallum Institutional Investor Conference
Participating on Wednesday, June 2, 2021
About DermTech:
DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.DermTech.com.
Forward-Looking Statements:
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: DermTech’s plans to attend investor conferences, and the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech’s products and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Quarterly Report on Form 10-Q filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210518006066/en/
FAQ
When will DermTech present at the 41st Annual William Blair Growth Stock Conference?
How can I access DermTech's presentation from the William Blair conference?
What is DermTech's participation in the Craig-Hallum Institutional Investor Conference?
What is DermTech's focus in dermatology?
Where can I find more information about DermTech?
